Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

But the man’s condition worsened, progressing into cirrhosis and eventually hepatocellular carcinoma, also known as liver ...

Exelixis, Inc. EXEL announced that the FDA has notified it about an update to its supplemental new drug application (sNDA) ...

"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...

Liver cells attempt to shut down as a defense mechanism against cancer, but this strategy is not particularly effective.

The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, ...

There’s a stigma surrounding liver cancer. Once you tell people you’ve got it, often you sense a slight judgment. “Oh”, you ...

The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the ...

Yang Zhang, Ph.D., and Jinjun Shi, Ph.D., both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative ...